April, 2020
rss twitter facebook Linkedin

As France's leading biocluster for health, Genopole is mobilizing all its forces in the battle against COVID-19.
This unprecedented health crisis before us leads me to express my deep gratitude to the unyielding laboratories and companies that, through their expertise and support for the development and deployment of equipment, materials, reagents and diagnostic aids, have been assisting our hospitals since day one.

Through the initiative "Genopole Solidarity" , more than 70,000 gloves, 3000 masks, 15,000 gowns, 1000 caps and numerous bottles of hand sanitizer have been delivered to our neighbor and partner, the South Île-de-France Medical Center (CHSF).

To do their part for the French government's objective of implementing massive screening, the businesses and academic labs at Genopole are uniting their energy, equipment and technical & scientific know-how to establish a large-scale COVID-19 screening center at the biocluster to detect carriers of the virus.

Genopole will continue to coordinate its actions and activate its networks for the duration of this health crisis. To our researchers, entrepreneurs, employees, administrators, partners, service providers and officeholders, thank you for your efforts!

Together, we can and will continue to do our part in the battle against COVID-19.

Anne Jouvenceau, Acting Director General

Battle against COVID-19

Toward a Candidate Vaccine for COVID-19
The Quebecois company Medicago successfully produced coronavirus-like particles in only 20 days thanks to its exclusive, plant-based high-throughput production process. That exploit is an important stepping stone in the company's development of a COVID-19 vaccine, for which human clinical trials could be launched as early as summer 2020. Medicago is also developing anti-COVID-19 antibodies to treat infected patients. Medicago is a partner of Pymabs, a Genopole R&D company specialized in the plant-based production of monoclonal antibodies. Pymabs is equipped with Medicago's discovery platform. "I'm delighted for this success by Medicago," commented Pymabs CEO Andéol Falcon. "Their unique technology enables the rapid development of candidate vaccines and eases the passage from research to GMP pharmaceutical production; those aspects will be particularly salutary for the current COVID-19 pandemic and beyond."
On March 21, Medicago welcomed financial support from the Government of Quebec for the development of a vaccine against COVID-19.
Read more {...}

Pharnext Announces Identification of a Large Set of Frequently Prescribed Drugs to be Repurposed for Fighting COVID-19, Using its Pleotherapy™ Platform
Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today announced the identification of 97 frequently prescribed drugs as potential candidates to be repositioned for treating COVID-19 through the use of its Pleotherapy™ platform.
Read more {...}

Genopole wins the Cosme Go International
The Genopole-coordinated European project GEN.ERA (diGital gENomic alliance to Explore new maRkets for Acceleration) has been selected by the European Commission. GEN.ERA seeks to harness inter-cluster cooperation for the internationalization of genomics companies beyond European borders.
The project, which will lay a path toward European-level partnerships in genomics, represents an important step for Genopole in its international goals.

Read more {...} read more

Algentech Granted US Patent For A Key Genome Editing Technology

ALGENTECH, announces the issuance of a key patent in the field of genome editing by the U.S. Patent Office (U.S. patent number 10457950).
The technology claimed by the patent amplifies the effectiveness of gene editing in eukaryotic cells and can be applied in synergy with nucleases, including zinc finger nucleases, TALENs, Crispr-Cas9...

Read more {...} read more

The Janssen Team Visited Genopole
Genopole was pleased to welcome an international team from Janssen, including: Emmanuelle Quilès - managing director, Janssen France; Gunaretnam Rajagopal - vice president and head of computational sciences, Janssen Global Discovery; Virginie Lasserre - government affairs manager, Janssen France; Siau Bai - medical strategy & partnerships director, Janssen France; Tahera Kan - senior director corporate development, Janssen Global Business Development.
The Janssen team met with Genopole representatives and visited its laboratories and companies to better understand the biocluster's ecosystem, share mutual interests in science and technologies and find potential partners.

QC Genomics: a public web portal for functional genomics data
QC Genomics

The scientific community now benefits from an unprecedented public web portal providing access to a cornucopia of genome sequencing and expression data.
Housed at Genopole, this portal called QC Genomics was developed by Marco Antonio Mendoza-Parra, who heads a new Genopole research team within the Genomics Metabolics lab. (Genoscope, CEA/CNRS/University of Évry).

Genethon announces expanded collaboration with Sarepta Therapeutics for continued development of an innovative gene therapy for Duchenne muscular dystrophy

Genethon, a French laboratory dedicated to the design and development of gene therapy products for rare diseases, and Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, today announced an expansion of their collaboration to develop a gene therapy approach for Duchenne muscular dystrophy. Microdystrophin has demonstrated significant efficacy in pre-clinical testing*. The agreement between Sarepta and Genethon paves the way for a clinical trial to begin in 2020.

Read more {...} read more
Conclusive Results of a Gene Therapy Trial in Chronic Septic Granulomatosis

Genethon, which developed the lentiviral vector used and sponsored initial clinical studies, is pleased with the conclusive results of the gene therapy trial underway in the United States and England in X-linked Chronic Septic Granulomatosis (X-CGD), a rare and severe immune dysfunction.

Six of the nine patients are free of treatments related to complications generated by the disease. These results have been published in Nature Medicine

Read more {...} read more
CNRGH: Emergency Gene Sequencing Enables Accelerated Diagnoses in Pediatrics

Researchers from the National Center of Human Genomics Research (CEA-CRNGH) established on the Genopole biocluster, the Dijon Bourgogne University Hospital and Inserm's U1231 GAD unit demonstrated the interest of emergency whole-genome sequencing in a pilot study involving 30 newborns placed in neonatal intensive care. In their study, the team was able to greatly reduce the time needed for sequencing and provide diagnoses for two-thirds of the newborns.
The work confirms the feasibility and the benefits of emergency high throughput sequencing for ensuring rapid and pertinent medical care.

Genopole and the Mediterranean region - The Next Society
28-30 January 2020

Invited by its Tunisian partner BiotechPole Sidi Thabet, Genopole participated actively in the inauguration of the Pharma In cluster held 28 January 2020. BiotechPole Sidi Thabet is a technology cluster for biotechnologies, pharmaceuticals & parapharmaceuticals, life sciences and healthcare engineering.

As Tunisia's leading motor for innovation in its fields of specialization, BiotechPole Sidi Thabet is looking to strengthen its activities for the development of partnerships between the three pillars of innovation: business, R&D and training.

To forward that goal at the inauguration, BiotechPole Sidi Thabet requested Genopole's aid for the consolidation of its Fablab and for the structuration of its entrepreneurship activities.
Chosen within the European program "The Next Society", Genopole furthermore met with European and Mediterranean-region clusters during the second edition of Techdays, held 28–30 January 2020 in Tunis, to share good practices and imagine future industrial and research partnerships.

Read more {...} read more read more

Genopole Visits North Carolina Biotech Center and HudsonAlpha Institute for Biotechnology, United States, 3-5 February 2020

Representatives from Genopole met with their peers at the North Carolina Biotechnology Center (NCBiotech) at Research Triangle Park, America's leading research cluster.


The meeting was an opportunity to identify the needs of the companies within the two entities as concerns a soft-landing convention and the possibilities of joint research with Duke University and the University of North Carolina.
The NCBiotech team had visited Genopole in October 2019. During their trip to the US, the Genopole representatives also visited the HudsonAlpha Institute for Biotechnology, another specialist in genomics with which inter-business partnerships already exist, such as that between the Genopole company Wiratech and the HudsonAlpha company iRepertoire.
An upcoming convention in San Diego in June and the yearly NCBiotech conference in September will be key opportunities to create concrete partnerships between companies at Genopole and those at these two American counterparts.
Life innovation center japan

Life Innovation Center Delegation Visits Genopole, 13 February 2020

A delegation from the Kanagawa Life Innovation Center, including its director and members of the center's business promotion agency, visited Genopole to better understand how its ecosystem functions and find complementarities between the two structures.
The Life Innovation Center is located in the Japanese city of Kawasaki (Kanagawa Prefecture), which is home to numerous innovative companies and labs.
Like in Osaka, that concentration of innovation creates a fertile environment for soft landings, business incubation and access to shared standard equipment. In turn, a delegation from Genopole will soon visit the Life Innovation Center to deepen discussions on concrete partnership between the two entities' businesses and laboratories.

Summer School in Bioinformatics and Biostatistical Tools in Medical Genomics - 22-25 June 2020

The programme will cover statistical methodologies and bioinformatics tools used in genomics ans metagenomics in the context of a comprehensive approach to pathologocal mechanisms. The courses will include lectures by guest speakers as well as hands on computer sessions with experts scientists and international leaders in the field.
[+] Topics &speakers

Summer School
The course is intended for researchers, engineers, PhD students and post-docs already in or planning to start their research project in the field of genomics for medical research.
[+] How to apply
Read more {...} read more
Visa4biotech Singapore - 24 June 2020

Visa4biotech program

Genopole invites you to a morning Visa4Biotech on market issues and opportunities for biotech and health in Singapore.
The program, which will emphasize intellectual and industry property, was organized with the French Chamber of Commerce in Singapore (FCCS), the French Embassy in Singapore and the Singapore Embassy in France, The Singapore Economic Development Board (EDB), the National Institute for Intellectual Property (INPI) and the DS Avocats law firm.
The event will include a roundtable with the Genopole start-up Gourmey, CellProthéra (which has an affiliate in Singapore) and IPSEN as a pharmaceutical company present in Singapore.

We look forward to seeing you there! {...} read more
Bioket, Lille, France - 30 June - 2 July 2020

The Global Conference dedicated to processes and technologies applied to Biomass, initially planned on March 10, has been rescheduled to take place on 30 June till 2 July in Lille. Genopole will be present at this global conference. Do not hesitate to visit us!

  For additional information, please write to
  Sandrine RUBIO
Communication department
Aurélie SEGUIN
International department